RDHL
Income statement / Annual
Last year (2023), RedHill Biopharma Ltd.'s total revenue was $6.51 M,
a decrease of 89.46% from the previous year.
In 2023, RedHill Biopharma Ltd.'s net income was $23.92 M.
See RedHill Biopharma Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$6.51 M |
$61.80 M |
$85.76 M |
$64.36 M |
$6.29 M |
$8.36 M |
$4.01 M |
$101,000.00 |
$3,000.00 |
$7.01 M |
| Cost of Revenue |
$3.46 M
|
$33.34 M
|
$49.41 M
|
$36.89 M
|
$2.26 M
|
$2.84 M
|
$2.13 M
|
$30.54 M
|
$22.00 M
|
$1.05 M
|
| Gross Profit |
$3.05 M
|
$28.46 M
|
$36.35 M
|
$27.47 M
|
$4.03 M
|
$5.52 M
|
$1.88 M
|
-$30.44 M
|
-$22.00 M
|
$5.96 M
|
| Gross Profit Ratio |
0.47
|
0.46
|
0.42
|
0.43
|
0.64
|
0.66
|
0.47
|
-301.41
|
-7333
|
0.85
|
| Research and Development Expenses |
$3.52 M
|
$7.28 M
|
$29.50 M
|
$16.49 M
|
$17.42 M
|
$24.86 M
|
$32.97 M
|
$25.24 M
|
$17.77 M
|
$12.70 M
|
| General & Administrative Expenses |
$28.88 M
|
$54.97 M
|
$76.60 M
|
$25.38 M
|
$11.48 M
|
$7.51 M
|
$8.03 M
|
$5.40 M
|
$4.13 M
|
$4.01 M
|
| Selling & Marketing Expenses |
$2.10 M
|
$9.06 M
|
$11.39 M
|
$49.29 M
|
$18.33 M
|
$12.49 M
|
$12.01 M
|
$1.56 M
|
$1.39 M
|
$0.00
|
| Selling, General & Administrative Expenses |
$30.98 M
|
$64.03 M
|
$87.99 M
|
$74.66 M
|
$29.81 M
|
$19.99 M
|
$20.04 M
|
$5.40 M
|
$4.13 M
|
$4.01 M
|
| Other Expenses |
-$44.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$845,000.00
|
$0.00
|
$100,000.00
|
-$100,000.00
|
| Operating Expenses |
-$9.56 M
|
$71.31 M
|
$117.49 M
|
$91.15 M
|
$47.23 M
|
$44.85 M
|
$53.85 M
|
$30.64 M
|
$22.01 M
|
$16.61 M
|
| Cost And Expenses |
-$6.10 M
|
$104.64 M
|
$166.89 M
|
$128.04 M
|
$49.49 M
|
$47.69 M
|
$55.98 M
|
$30.64 M
|
$22.01 M
|
$17.66 M
|
| Interest Income |
$93,757.00
|
$140,000.00
|
$51,000.00
|
$270,000.00
|
$1.34 M
|
$678,000.00
|
$6.51 M
|
$1.55 M
|
$1.12 M
|
$319,000.00
|
| Interest Expense |
$367,000.00
|
$41.33 M
|
$16.57 M
|
$12.76 M
|
$438,000.00
|
$167,000.00
|
$77,000.00
|
$375,000.00
|
$212,000.00
|
$383,000.00
|
| Depreciation & Amortization |
$1.99 M
|
$8.12 M
|
$18.16 M
|
$8.81 M
|
$1.22 M
|
$89,707.00
|
$81,573.00
|
$44,138.00
|
$36,000.00
|
$27,000.00
|
| EBITDA |
$26.31 M |
-$42.84 M |
-$63.03 M |
-$54.94 M |
-$40.78 M |
-$38.60 M |
-$45.79 M |
-$30.50 M |
-$21.87 M |
-$10.62 M |
| EBITDA Ratio |
4.04
|
-0.69
|
-0.73
|
-0.85
|
-6.48
|
-4.62
|
-11.43
|
-301.97
|
-7288.67
|
-1.51
|
| Operating Income Ratio |
1.94
|
-0.69
|
-0.95
|
-0.99
|
-6.87
|
-4.7
|
-12.97
|
-302.41
|
-7334
|
-1.52
|
| Total Other Income/Expenses Net |
$11.32 M
|
-$28.83 M
|
-$16.61 M
|
-$12.49 M
|
$897,000.00
|
$511,000.00
|
$6.43 M
|
$1.17 M
|
$812,000.00
|
-$64,000.00
|
| Income Before Tax |
$23.95 M
|
-$71.67 M
|
-$97.74 M
|
-$76.17 M
|
-$42.30 M
|
-$38.82 M
|
-$45.54 M
|
-$29.37 M
|
-$21.09 M
|
-$10.71 M
|
| Income Before Tax Ratio |
3.68
|
-1.16
|
-1.14
|
-1.18
|
-6.72
|
-4.64
|
-11.37
|
-290.79
|
-7030
|
-1.53
|
| Income Tax Expense |
$0.00
|
-$12.42 M
|
$16.57 M
|
$12.84 M
|
$1.33 M
|
$727,000.00
|
$6.29 M
|
$1.27 M
|
$900,000.00
|
$222,000.00
|
| Net Income |
$23.92 M
|
-$59.25 M
|
-$114.31 M
|
-$89.02 M
|
-$43.63 M
|
-$38.82 M
|
-$45.54 M
|
-$29.37 M
|
-$21.09 M
|
-$10.71 M
|
| Net Income Ratio |
3.67
|
-0.96
|
-1.33
|
-1.38
|
-6.94
|
-4.64
|
-11.37
|
-290.79
|
-7030
|
-1.53
|
| EPS |
4 |
-38.27 |
-98.27 |
-97.75 |
-58.78 |
-68 |
-104 |
-94.96 |
-76.13 |
-49.47 |
| EPS Diluted |
4 |
-38.27 |
-98.27 |
-97.75 |
-58.78 |
-68 |
-104 |
-92 |
-75.51 |
-49.12 |
| Weighted Average Shares Out |
$6.48 M
|
$1.55 M
|
$1.16 M
|
$910,690.00
|
$742,304.00
|
$570,882.00
|
$437,923.00
|
$309,299.00
|
$277,035.00
|
$216,525.00
|
| Weighted Average Shares Out Diluted |
$6.48 M
|
$1.55 M
|
$1.16 M
|
$910,690.00
|
$742,304.00
|
$570,882.00
|
$437,923.00
|
$319,239.00
|
$279,288.00
|
$218,055.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
